Literature DB >> 33407694

Noncoding RNAs regulate alternative splicing in Cancer.

Yunze Liu1,2, Xin Liu3, Changwei Lin4, Xianhong Jia2, Hongmei Zhu2, Jun Song5, Yi Zhang6.   

Abstract

AS (alternative splicing) is a fundamental process by which a gene can generate multiple distinct mRNA transcripts to increase protein diversity. Defects in AS influence the occurrence and development of many diseases, including cancers, and are frequently found to participate in various aspects of cancer biology, such as promoting invasion, metastasis, apoptosis resistance and drug resistance. NcRNAs (noncoding RNAs) are an abundant class of RNAs that do not encode proteins. NcRNAs include miRNAs (microRNAs), lncRNAs (long noncoding RNAs), circRNAs (circular RNAs) and snRNAs (small nuclear RNAs) and have been proven to act as regulatory molecules that mediate cancer processes through AS. NcRNAs can directly or indirectly influence a plethora of molecular targets to regulate cis-acting elements, trans-acting factors, or pre-mRNA transcription at multiple levels, affecting the AS process and generating alternatively spliced isoforms. Consequently, ncRNA-mediated AS outcomes affect multiple cellular signaling pathways that promote or suppress cancer progression. In this review, we summarize the current mechanisms by which ncRNAs regulate AS in cancers and discuss their potential clinical applications as biomarkers and therapeutic targets.

Entities:  

Keywords:  Alternative splicing; Cancer; Noncoding RNA; circRNA; lncRNA; miRNA; snRNA

Year:  2021        PMID: 33407694     DOI: 10.1186/s13046-020-01798-2

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  130 in total

Review 1.  Alternative splicing and evolution: diversification, exon definition and function.

Authors:  Hadas Keren; Galit Lev-Maor; Gil Ast
Journal:  Nat Rev Genet       Date:  2010-04-08       Impact factor: 53.242

2.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Authors:  Garrett M Frampton; Siraj M Ali; Mark Rosenzweig; Juliann Chmielecki; Xinyuan Lu; Todd M Bauer; Mikhail Akimov; Jose A Bufill; Carrie Lee; David Jentz; Rick Hoover; Sai-Hong Ignatius Ou; Ravi Salgia; Tim Brennan; Zachary R Chalmers; Savina Jaeger; Alan Huang; Julia A Elvin; Rachel Erlich; Alex Fichtenholtz; Kyle A Gowen; Joel Greenbowe; Adrienne Johnson; Depinder Khaira; Caitlin McMahon; Eric M Sanford; Steven Roels; Jared White; Joel Greshock; Robert Schlegel; Doron Lipson; Roman Yelensky; Deborah Morosini; Jeffrey S Ross; Eric Collisson; Malte Peters; Philip J Stephens; Vincent A Miller
Journal:  Cancer Discov       Date:  2015-05-13       Impact factor: 39.397

Review 3.  Alternative splicing: a pivotal step between eukaryotic transcription and translation.

Authors:  Alberto R Kornblihtt; Ignacio E Schor; Mariano Alló; Gwendal Dujardin; Ezequiel Petrillo; Manuel J Muñoz
Journal:  Nat Rev Mol Cell Biol       Date:  2013-02-06       Impact factor: 94.444

Review 4.  Mechanisms and Regulation of Alternative Pre-mRNA Splicing.

Authors:  Yeon Lee; Donald C Rio
Journal:  Annu Rev Biochem       Date:  2015-03-12       Impact factor: 23.643

Review 5.  Alternative splicing in cancers: From aberrant regulation to new therapeutics.

Authors:  Xiaowei Song; Zhenyu Zeng; Huanhuan Wei; Zefeng Wang
Journal:  Semin Cell Dev Biol       Date:  2017-09-14       Impact factor: 7.727

6.  Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing.

Authors:  Xinping Yang; Jasmin Coulombe-Huntington; Shuli Kang; Gloria M Sheynkman; Tong Hao; Aaron Richardson; Song Sun; Fan Yang; Yun A Shen; Ryan R Murray; Kerstin Spirohn; Bridget E Begg; Miquel Duran-Frigola; Andrew MacWilliams; Samuel J Pevzner; Quan Zhong; Shelly A Trigg; Stanley Tam; Lila Ghamsari; Nidhi Sahni; Song Yi; Maria D Rodriguez; Dawit Balcha; Guihong Tan; Michael Costanzo; Brenda Andrews; Charles Boone; Xianghong J Zhou; Kourosh Salehi-Ashtiani; Benoit Charloteaux; Alyce A Chen; Michael A Calderwood; Patrick Aloy; Frederick P Roth; David E Hill; Lilia M Iakoucheva; Yu Xia; Marc Vidal
Journal:  Cell       Date:  2016-02-11       Impact factor: 41.582

Review 7.  Evolution of SR protein and hnRNP splicing regulatory factors.

Authors:  Anke Busch; Klemens J Hertel
Journal:  Wiley Interdiscip Rev RNA       Date:  2011-09-02       Impact factor: 9.957

8.  The Functional Impact of Alternative Splicing in Cancer.

Authors:  Héctor Climente-González; Eduard Porta-Pardo; Adam Godzik; Eduardo Eyras
Journal:  Cell Rep       Date:  2017-08-29       Impact factor: 9.423

Review 9.  Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

Authors:  Laura M Urbanski; Nathan Leclair; Olga Anczuków
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-04-25       Impact factor: 9.957

Review 10.  Splicing regulation by long noncoding RNAs.

Authors:  Natali Romero-Barrios; Maria Florencia Legascue; Moussa Benhamed; Federico Ariel; Martin Crespi
Journal:  Nucleic Acids Res       Date:  2018-03-16       Impact factor: 16.971

View more
  24 in total

1.  Decoding the concealed transcriptional signature of the apoptosis-related BCL2 antagonist/killer 1 (BAK1) gene in human malignancies.

Authors:  Konstantina Athanasopoulou; Panagiotis G Adamopoulos; Glykeria N Daneva; Andreas Scorilas
Journal:  Apoptosis       Date:  2022-07-25       Impact factor: 5.561

Review 2.  Circular RNAs as novel biomarkers in triple-negative breast cancer: a systematic review.

Authors:  Zahra Foruzandeh; Davood Ghavi Dorabadi; Farzaneh Sadeghi; Fatemeh Zeinali-Sehrig; Mohammad Zaefizadeh; Yazdan Rahmati; Mohammad Reza Alivand
Journal:  Mol Biol Rep       Date:  2022-05-10       Impact factor: 2.742

3.  Competing endogenous RNA networks related to prognosis in chronic lymphocytic leukemia: comprehensive analyses and construction of a novel risk score model.

Authors:  Xin Zhang; Yang Han; Xinting Hu; Hua Wang; Zheng Tian; Ya Zhang; Xin Wang
Journal:  Biomark Res       Date:  2022-10-21

4.  Jatrorrhizine can improve nerve cell injury induced by Aβ 25-35, acting through miR-223-3p/HDAC4 axis.

Authors:  Wenbiao Duan; Xue Chen
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

Review 5.  Circular RNAs as Novel Regulators of β-Cell Functions under Physiological and Pathological Conditions.

Authors:  Flora Brozzi; Romano Regazzi
Journal:  Int J Mol Sci       Date:  2021-02-03       Impact factor: 5.923

Review 6.  The Role of NcRNAs to Regulate Immune Checkpoints in Cancer.

Authors:  Yicun Jiang; Leilei Zhao; Yiwen Wu; Sijun Deng; Pu Cao; Xiaoyong Lei; Xiaoyan Yang
Journal:  Front Immunol       Date:  2022-04-06       Impact factor: 8.786

Review 7.  Bioinformatic Tools for the Analysis and Prediction of ncRNA Interactions.

Authors:  Andrés Rincón-Riveros; Duvan Morales; Josefa Antonia Rodríguez; Victoria E Villegas; Liliana López-Kleine
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923

8.  Circular RNA: A novel type of biomarker for glioma (Review).

Authors:  Wei Sun; Huandi Zhou; Xuetao Han; Liubing Hou; Xiaoying Xue
Journal:  Mol Med Rep       Date:  2021-06-24       Impact factor: 2.952

9.  Overexpression of miR-1306-5p, miR-3195, and miR-3914 Inhibits Ameloblast Differentiation through Suppression of Genes Associated with Human Amelogenesis Imperfecta.

Authors:  Hiroki Yoshioka; Yin-Ying Wang; Akiko Suzuki; Meysam Shayegh; Mona V Gajera; Zhongming Zhao; Junichi Iwata
Journal:  Int J Mol Sci       Date:  2021-02-23       Impact factor: 5.923

10.  CircRERE confers the resistance of multiple myeloma to bortezomib depending on the regulation of CD47 by exerting the sponge effect on miR-152-3p.

Authors:  Wei Fang; Jiao Mu; Yi Yang; Lin Liu
Journal:  J Bone Oncol       Date:  2021-07-08       Impact factor: 4.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.